


Intravenous (IV) Iron Drugs Market to Reach US\$6.6 Bn by 2032 at 8.7% CAGR | Persistence Market Research

BRENFORD, LONDON , UNITED KINGDOM, July 8, 2026

/EINPresswire.com/ -- The [Intravenous \(IV\) Iron Drugs Market](#) is expanding steadily as healthcare providers increasingly adopt intravenous iron therapy for the treatment of iron deficiency and iron deficiency anemia. Patients suffering from chronic kidney disease, gastrointestinal disorders, cancer-related anemia, and conditions that limit oral iron absorption are driving higher demand for IV iron drugs. Modern formulations provide faster iron replenishment, improved safety, and better patient outcomes, making them a preferred treatment option in hospitals and specialty healthcare settings. Continuous advancements in pharmaceutical formulations and growing awareness among physicians are supporting long-term market growth.



According to Persistence Market Research, the global Intravenous (IV) Iron Drugs Market is likely to be valued at US\$3.7 Bn in 2025 and is expected to reach US\$6.6 Bn by 2032, growing at a CAGR of 8.7% during the forecast period from 2025 to 2032. Rising healthcare investments, increasing diagnosis of iron deficiency, and wider availability of advanced infusion therapies are strengthening market expansion. Hospitals remain the leading end-user due to high treatment volumes and specialized facilities, while North America leads the market because of advanced healthcare infrastructure, favorable reimbursement policies, and higher awareness of anemia management.

Want Market Insights? Get Your Free Report Sample :

<https://www.persistencemarketresearch.com/samples/2829>

Key Highlights from the Report

- The Intravenous (IV) Iron Drugs Market is projected to grow from US\$3.7 Bn in 2025 to US\$6.6 Bn by 2032, registering a CAGR of 8.7%.
- Rising prevalence of iron deficiency anemia is increasing the demand for intravenous iron therapies globally.
- Advanced IV iron formulations are improving treatment efficiency and patient convenience.
- Hospitals continue to dominate the market owing to higher patient admissions requiring infusion therapies.
- North America remains the leading regional market due to strong healthcare infrastructure and reimbursement support.
- Continuous pharmaceutical innovation is creating long-term growth opportunities.

Market Segmentation

The Intravenous (IV) Iron Drugs Market is segmented by product type, application, and end user. Various intravenous iron formulations are available to improve treatment effectiveness while minimizing adverse reactions. These therapies are widely prescribed for patients with chronic diseases, pregnancy-related anemia, surgical blood loss, and gastrointestinal disorders where oral supplements are ineffective. Growing physician preference for rapid iron replacement is increasing product adoption.

Based on end users, hospitals account for the largest market share because they provide advanced infusion facilities and specialist care. Specialty clinics and ambulatory infusion centers are also witnessing growing demand due to increasing outpatient treatment services. Better diagnosis rates, improved healthcare accessibility, and rising awareness regarding iron deficiency continue to support demand across healthcare settings.

Regional Insights

North America dominates the Intravenous (IV) Iron Drugs Market due to well-developed healthcare infrastructure, greater awareness regarding anemia treatment, and widespread adoption of advanced infusion therapies. The presence of leading pharmaceutical companies and supportive reimbursement policies further strengthen market leadership.

Europe continues to witness healthy growth through increasing healthcare expenditure and an aging population. Meanwhile, Asia Pacific is emerging as a promising market due to improving healthcare infrastructure, rising patient awareness, growing diagnosis rates, and expanding access to specialty treatments across developing countries.

Customize This Report for Your Exact Requirements :

<https://www.persistencemarketresearch.com/request-customization/2829>

Market Drivers

The increasing prevalence of iron deficiency anemia remains the primary driver of the Intravenous (IV) Iron Drugs Market. Chronic kidney disease, inflammatory bowel disease, pregnancy complications, and oncology treatments continue to increase demand for rapid and

effective iron replacement therapies. Physicians increasingly recommend intravenous treatment when oral iron supplements fail or cannot be tolerated.

Continuous product innovation also supports market expansion. Pharmaceutical companies are introducing advanced formulations with improved safety profiles, shorter infusion times, and greater dosing convenience. Rising healthcare spending, improved diagnostic capabilities, and increasing adoption of evidence-based treatment practices further accelerate market growth.

Unlock Complete Insights – Buy the Full Report :

<https://www.persistencemarketresearch.com/checkout/2829>

Market Restraints

Higher treatment costs compared to oral iron supplements remain a major challenge for market expansion. Intravenous therapies require trained healthcare professionals and infusion facilities, increasing the overall cost of treatment. Limited affordability in developing healthcare systems may reduce patient access.

Regulatory requirements for pharmaceutical approvals and ongoing safety monitoring may also delay product launches. Pricing pressure from healthcare providers and reimbursement agencies, along with competition from alternative anemia management approaches, can affect manufacturer profitability and limit faster market expansion.

Market Opportunities

Growing awareness regarding early diagnosis and preventive healthcare creates significant opportunities for the Intravenous (IV) Iron Drugs Market. Increasing adoption of outpatient infusion services provides convenient treatment options while reducing hospital stays and improving patient satisfaction.

Emerging economies offer attractive growth potential as governments continue investing in healthcare infrastructure and specialty medicine access. Continued research, strategic collaborations, and the development of innovative IV iron formulations are expected to support future market expansion and improve patient outcomes worldwide.

Company Insights

Key players operating in the market include CSL Vifor, Daiichi Sankyo Company, Limited, Pharmacosmos A/S, Sanofi, Covis Pharma, Shield Therapeutics plc, American Regent, Inc., Rockwell Medical, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd., Lupin Limited, Viatrix Inc., Cipla Limited, Sandoz, and Gland Pharma.

Explore the Latest Trending Research Reports:

[Lyophilization Equipment Market](#)

[Obesity GLP-1 Market](#)

Persistence Market Research
Persistence Market Research Pvt Ltd
+1 646-878-6329

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/925172428>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.